By Sheeba M. | April 19, 2026
Verano Holdings Posts Q1 2026: $280M Revenue and the Path to Becoming the US’s #2 Cannabis Operator
Verano Holdings VRNOF released its Q1 2026 earnings this week, posting $280 million in revenue — a 22% year-over-year jump that puts the Chicago-based MSO firmly in contention for the second-largest cannabis operator title in the United States. Adjusted EBITDA came in at $42 million, marking the fourth consecutive quarter of positive operating cash flow.
What’s Driving the Numbers
The core growth engine is straightforward: more stores, more throughput per store. Verano opened 12 new dispensaries in Q1, bringing its total retail count to 212 across 14 states. The company’s ZenLeaf and MÜV branded locations are showing strong comparable-store sales growth of 8% quarter-over-quarter, a sign that brand loyalty is deepening even as new competitors enter mature markets.
On the product side, Verano’s house-of-brands strategy continues to pay dividends. Proprietary strains now account for 38% of flower sales, up from 29% a year ago, and concentrate cartridge sell-through has been boosted by the company’s expanding partnership with select state-licensed extraction operators.
The Acquisition Stack
Verano closed two key acquisitions in Q1: a vertically integrated operator in Virginia and a mid-size MSO with strong medical dispensary presence in Pennsylvania. Neither deal broke the bank — combined consideration was approximately $85 million in cash and stock — but both unlock addressable markets that will contribute revenue starting Q3 2026.
The Virginia play is particularly interesting. The state’s adult-use market is expected to launch mid-2026, and Verano’s vertically integrated Virginia assets (cultivation, processing, retail) give it a head start on competitors still scrambling to secure supply agreements.
Can VRNOF Catch Trulieve?
Trulieve still holds the #2 revenue slot nationally, and its dominance in Florida — a massive single-state market — is hard to replicate overnight. But VRNOF is picking away at the gap. Its multi-state footprint is broader than Trulieve’s, and the recent acquisitions give it better geographic diversification. If Florida’s market softens or recedes, Trulieve’s revenue concentration becomes a liability; Verano’s spread becomes an asset.
Wall Street consensus price target for VRNOF sits at $8.50, implying roughly 40% upside from current levels. The stock trades at roughly 3x forward EV/Revenue — below the MSO peer average of 4x — suggesting there’s still room for multiple expansion if execution holds.
Bottom Line
Verano is doing the right things: growing revenue, staying EBITDA-positive, stacking acquisitions in high-value markets, and building out its brand portfolio. The Q1 print was clean. Watch for Q2 guidance when the company reports in late May — any upward revision to the full-year revenue outlook could be the catalyst investors have been waiting for.
Track VRNOF alongside the rest of the MSO universe on the Weedstock Real-Time Tracker.
Sources
- Verano Holdings IR — Q1 2026 earnings press release
- SEC EDGAR — VRNOF 10-Q filing (Q1 2026)
- Leafly State Cannabis Reports — Virginia market analysis
Track cannabis stocks with the Weedstock Real-Time Tracker